Penn researchers use AI to accelerate RNA drug development
University of Pennsylvania researchers have launched an AI-driven research hub to accelerate the development of RNA-based therapies. The hub aims to democratize RNA technology and reduce technical barriers to its use.
The University of Pennsylvania has established a new research hub to accelerate the development of RNA-based therapies using artificial intelligence. The $18 million NSF-funded initiative brings together researchers to design and test lipid nanoparticles that deliver RNA-based treatments. The hub aims to 'democratize RNA technology' by reducing technical barriers and creating an open platform for researchers to learn and share results. Researchers will use AI and automation to improve predictive systems and reduce trial-and-error testing, speeding up drug development. The project builds on Penn's existing expertise in mRNA vaccines, which were developed by professors Katalin Karikó and Drew Weissman. By creating a shared institute for collaboration, the hub hopes to drive innovation and improve RNA-based therapies.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.